Skip to content

Study of High-flow Oxygen Therapy Against Standard Therapy in Bronchiolitis

A Prospective Open Randomized Clinical Trial Comparing High Flow Nasal Cannula Oxygen Therapy Against Standard Therapy for Children Hospitalized With Bronchiolitis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01498094
Acronym
Hi-Flo
Enrollment
79
Registered
2011-12-23
Start date
2011-12-31
Completion date
2014-12-31
Last updated
2015-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiolitis

Keywords

Bronchiolitis, High, Flow, Oxygen, Therapy, Nasal, Cannulae, Prongs

Brief summary

Bronchiolitis is a common illness of the respiratory tract caused by infection of the tiny airways within the lungs called bronchioles. At present the standard care of hospitalized children with bronchiolitis is oxygen via nasal prongs. In this study the investigators would like to compare standard ward management with a new method of delivering oxygen called high flow nasal cannula oxygen therapy (HFNOT). HFNOT involves breathing warmed, moistened oxygen through nasal cannulae at a flow rate of 8 liters/minute. Accumulated experience suggests that HFNOT eases the child's work of breathing and reduces need for ICU admission and invasive respiratory support.

Detailed description

We propose a prospective open randomised controlled trial to compare high flow nasal cannula oxygen therapy (HFNOT) with standard oxygen therapy for infants hospitalised with bronchiolitis. This study will be the first of its kind, as currently there is no evidence in the published literature. All children will be cared for by the same medical team on two wards. All aspects of care other than oxygen delivery will not be specified, and be at the discretion of the physicians. HFNOT will not be used as an escalation of care on the wards. Randomisation will be performed by REDcap, in blocks of 6 patients. Patients will be identified in Emergency, informed consent obtained, and treatment started prior to transfer to the ward. For patients randomised to HFNOT, the flow rate will be fixed at 8 liters/minute, and the inspired oxygen concentration titrated to maintain saturations above 92%. Interim statistical analysis will be conducted to determine any positive or negative effect of HFNOT therapy. The first interval analysis will be performed after 50 subjects, the second after 100 subjects. If an effect is found, the study will be terminated following discussion with the hospital statistician and ethics board. Whichever treatment arm is found to be beneficial will be instituted as standard care for children with bronchiolitis.

Interventions

Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.

OTHERStandard low flow oxygen

Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Months
Healthy volunteers
No

Inclusion criteria

* All children under 18 months of age with a clinical diagnosis of bronchiolitis requiring admission to hospital for observation and oxygen.

Exclusion criteria

* Infants admitted directly to ICU from Emergency. * Prior positive pressure home ventilation. * Tracheostomy. * Nasogastric tubes in situ on admission. * Upper airway abnormality. * Congenital heart disease.

Design outcomes

Primary

MeasureTime frameDescription
Length of hospital stayExpected average length of stay 5 daysNumber of hours that the patient remains in hospital.

Secondary

MeasureTime frameDescription
Admission to Intensive Care UnitDuring hospitalisation for bronchiolitis, expected average 5 daysYes or No
Work of breathingDuring hospital stay, expected average 5 daysWork of breathing, assessed by respiratory rate, at four timepoints on day one, and daily thereafter

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026